To Be Discontinued Injection Rheumatology
Adalimumab-afzb Injection · 337 days since initial FDA posting
Brand: ABRILADA
FDA lists Adalimumab-afzb Injection as To Be Discontinued (Pfizer Inc.).
No availability text on this FDA row.
Adalimumab-afzb Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Adalimumab-afzb Injection
- Manufacturer
- Pfizer Inc.
- Dosage Form
- Injection
- Presentation
- Abrilada, Injection, Kit (NDC 0025-0325-01)
- Package NDC
- 0025-0325-01
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Oct 9, 2025
- Last Updated
- Oct 9, 2025
- Therapeutic Category
- Rheumatology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.